Benefits of using multiple first-line therapies against malaria

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 37, 2008, Pages 14216-14221

  Boni, Maciej F ^a,b   Smith, David L ^c,d   Laxminarayan, Ramanan ^a,b  

^a RESOURCES FOR THE FUTURE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c Princeton Environmental Institute ^*  (United States)

^d UNIVERSITY OF FLORIDA   (United States)

Author keywords

Cost of resistance; Drug resistance; Epidemiology; Evolution; Treatment strategies

Indexed keywords

ARTICLE; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG TREATMENT FAILURE; DRUG USE; EVOLUTIONARY ADAPTATION; HEALTH CARE POLICY; HOST; MALARIA; MATHEMATICAL COMPUTING; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MORBIDITY; MORTALITY; MULTIDRUG RESISTANCE; MULTIPLE FIRST LINE THERAPY; MUTATION RATE; PHARMACEUTICAL CARE; PRIORITY JOURNAL; THEORETICAL MODEL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTIMALARIALS; COMPUTER SIMULATION; HUMANS; MALARIA; MODELS, BIOLOGICAL; TIME FACTORS;

EID: 52949150087     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0804628105     Document Type: Article

References (43)

1. Talisuna AO, Bloland P, D'Alessandro U (2004) History, dynamics, and public health importance of malaria parasite resistance. Clin Microbiol Rev 17:235-254.
2. Gregson A, Plowe CV (2005) Mechanisms of resistance of malaria parasites to antifolates. Pharmacol Rev 57:117-145.
3. White NJ, et al. (1999) Averting a malaria disaster. Lancet 353:1965-1967.
4. White NJ (2008) Qinghaosu (Artemisinin): The price of Success. Science 320:330-334.
5. Institute of Medicine (2004) Saving Lives, Buying Time (Natl Academies Press, Washington, DC).
6. Amin A, et al. (2007) The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malaria J 6:72.
7. Shretta R, et al. (2000) Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 5:755-764.
8. Curtis CF, Otoo LN (1986) A simple model of the build-up of resistance to mixtures of anti-malarial drugs. Trans R Soc Trop Med Hyg 80:889-892.
9. Hastings IM, D'Alessandro U (2000) Modelling a predictable disaster: The rise and spread of drug-resistant malaria. Parasitol Today 16:340-347.
10. Hastings IM, Watkins WM, White NJ (2002) The evolution of drug-resistant malaria: The role of drug elimination half-life. Philos Trans R Soc Lond Ser B 357:505-519.
11. Mackinnon MJ, Hastings IM (1998) The evolution of multiple drug resistance in malaria parasites. Trans R Soc Trop Med Hyg 92:188-195.
12. Watkins WM, Sibley CH, Hastings IM (2005) The search for effective and sustainable treatments for Plasmodium falciparum malaria in Africa: A model of the selection of resistance by antifolate drugs and their combinations. Am J Trop Med Hyg 72:163-173.
13. White NJ (1998) Preventing antimalarial drug resistance through combinations. Drug Resist Updat 1:3-9.
14. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113:1084-1092.
15. White NJ, Pongtavornpinyo W (2003) The de novo selection of drug-resistant malaria parasites. Proc Biol Sci 270:545-554.
16. Bergstrom CT, Lo M, Lipsitch M (2004) Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 101:13285-13290.
17. Bonhoeffer S, Lipsitch M, Levin BR (1997) Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 94:12106-12111.
18. Laxminarayan R, Weitzman ML (2002) On the implications of endogenous resistance to medications. J Health Econ 21:709-718.
19. Smith DL, Boni MF, Laxminarayan R (2006) in Disease Evolution: Concepts, Models, Data Analyses, Feng Z, Dieckmann U, Levin S, eds (American Mathematical Society, Providence, RI), pp 213-237.
20. Bonhoeffer S (2002) in Adaptive Dynamics and Infectious Diseases: In Pursuit of Virulence Management, Dieckmann U, et al. eds (Cambridge Univ Press, Cambridge, UK), pp 326-338.
21. Cross AP, Singer B (1991) Modelling the development of resistance of Plasmodium falciparum to anti-malarial drugs. Trans R Soc Trop Med Hyg 85:349-355.
22. Anderson RM, May RM (1991) Infectious Diseases of Humans: Dynamics and Control (Oxford Science Publications, Oxford, UK).
23. Diekmann O, Heesterbeek JAP (2000) Mathematical Epidemiology of Infeectious Disease: Model Building, Analysis and Interpretation (Wiley, Chichester, UK).
24. Hastings IM (1997) A model for the origins and spread of drug-resistant malaria. Parasitology 115:133-141.
25. Hastings IM (2006) Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132: 615-624.
26. Dye C, Williams BG (1997) Multigenic drug resistance among inbred malaria parasites. Proc Biol Sci 264:61-67.
27. Githeko AK, et al.(1992) The reservoir of Plasmodium falciparum malaria in a holoendemic area of western Kenya. Trans R Soc Trop Med Hyg 86355-358.
28. Snow RW, Marsh K (2002) The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol 52:235-264.
29. Trape J-F, et al. (1994) The Dielmo Project: A longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg 51:123-137.
30. Eyles DE, Young MD (1951) The duration of intreated or inadequately treated Plasmodium falciparum infections in the human host. J Natl Malaria Soc 10: 327-336.
31. Smith DL, et al. (2005) The entomological inoculation rate and Plasmodium falciparum infection in African children. Nature 438:492-495.
32. Mackinnon MJ (2005) Drug resistance models for malaria. Acta Trop 94:207-217.
33. World Health Organization (WHO) (2006) Guidelines for the Treatment of Malaria (World Health Organization, Geneva).
34. Hastings IM, Donnelly MJ (2005) The impact of antimalarial drug resistance mutations on parasite fitness, and its implications for the evolution of resistance. Drug Resist Updat 8:43-50.
35. Plowe CV, Kublin JG, Doumbo OK (1998) P. falciparum dihydrofolate reductase and dihydropteroate synthase mutations: Epidemiology and role in clinical resistance to antifolates. Drug Resist Updat 1:389-396.
36. Barnes KI, White NJ (2005) Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop 94: 230-240.
37. Yekutiel P (1960) Problems of epidemiology in malaria eradication. Bull World Health Org 22:669-683.
38. Klein EY, et al. (2008) Clinically immune hosts as a refuge for drug-sensitive malaria parasites. Malaria J 7:67.
39. Marsh K, Snow RW (1999) Malaria transmission and morbidity. Parassitologia 41:241-246.
40. Hastings IM (2003) Malaria control and the evolution of drug resistance: An intriguing link. Trends Parasitol 19: 70-73.
41. Boni MF, Feldman MW (2005) Evolution of antibiotic resistance by human and bacterial niche construction. Evolution 59:477-491.
42. Odling-Smee FJ, Laland KN, Feldman MW (2003) Niche Construction the Neglected Process in Evolution (Princeton Univ Press, Princeton, NJ).
43. Schapira A, Beales PF, Halloran ME (1993) Malaria: Living with drug resistance. Parasitol Today 9:168-174.